Keene & Associates Inc. Sells 470 Shares of Avanos Medical, Inc. (NYSE:AVNS)

Keene & Associates Inc. trimmed its holdings in shares of Avanos Medical, Inc. (NYSE:AVNS) by 2.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,165 shares of the company’s stock after selling 470 shares during the quarter. Keene & Associates Inc.’s holdings in Avanos Medical were worth $437,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the business. William Blair Investment Management LLC increased its holdings in shares of Avanos Medical by 16.8% in the 1st quarter. William Blair Investment Management LLC now owns 1,425,036 shares of the company’s stock worth $28,372,000 after buying an additional 204,826 shares during the last quarter. Paradice Investment Management LLC raised its position in Avanos Medical by 5.4% during the second quarter. Paradice Investment Management LLC now owns 1,344,949 shares of the company’s stock valued at $26,791,000 after purchasing an additional 69,389 shares in the last quarter. Cornercap Investment Counsel Inc. purchased a new stake in Avanos Medical during the second quarter valued at about $1,077,000. Tributary Capital Management LLC lifted its stake in Avanos Medical by 7.5% during the first quarter. Tributary Capital Management LLC now owns 742,455 shares of the company’s stock worth $14,782,000 after purchasing an additional 51,865 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its holdings in shares of Avanos Medical by 314.4% in the 1st quarter. BNP Paribas Financial Markets now owns 53,583 shares of the company’s stock worth $1,067,000 after purchasing an additional 40,653 shares in the last quarter. 95.17% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised Avanos Medical from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, October 15th.

Avanos Medical Price Performance

AVNS opened at $22.35 on Thursday. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.28 and a quick ratio of 1.49. Avanos Medical, Inc. has a 1 year low of $17.24 and a 1 year high of $25.36. The stock’s 50 day simple moving average is $23.48 and its 200 day simple moving average is $21.42. The firm has a market cap of $1.03 billion, a price-to-earnings ratio of -16.80 and a beta of 0.91.

Avanos Medical (NYSE:AVNS) last issued its earnings results on Wednesday, July 31st. The company reported $0.34 EPS for the quarter, topping the consensus estimate of $0.29 by $0.05. The company had revenue of $171.70 million for the quarter, compared to the consensus estimate of $170.67 million. Avanos Medical had a net margin of 1.13% and a return on equity of 4.48%. The firm’s revenue for the quarter was up 1.4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.24 earnings per share. As a group, analysts predict that Avanos Medical, Inc. will post 1.39 earnings per share for the current year.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.